NEW YORK, April 11 – Biochip maker GeneScan of Freiburg Germany has acquired a minority stake in Oasis Biosciences of San Diego, Reuters reported Wednesday.

GeneScan, which paid $6 million for a “significant” holding in the company, also acquired the option to buy a majority stake in Oasis in one year’s time, Reuters said.

GeneScan acquired the stake in Oasis in order to gain a hold of its technology to improve the speed and reliability of biochips as it prepares to enter the pharmacogenomics sector.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.